Literature DB >> 6743467

Comparison of two long-acting forms of quinidine.

A Leizorovicz, C Piolat, J P Boissel, B Sanchini, S Ferry.   

Abstract

The bioequivalence of two forms of long acting quinidine compounds was assessed (Kinidin durules and Longacor) using drug plasma level and QT ECG changes. Six healthy volunteers received each preparation on two occasions in random order. The wash out period between successive experiments was at least 7 days. There was no difference in tmax, Cmax and AUC for plasma level and adjusted QT. However, between patient variability was large. A 20% difference in plasma levels could not be excluded but the difference in QT max and QT AUC between the two preparations did not exceed 20% (P less than 0.05, Westlake's method). This study illustrates the fact that pharmacodynamic equivalence, let alone therapeutic equivalence, does not necessarily imply plasma level equivalence, as assessed by the current method.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743467      PMCID: PMC1463434          DOI: 10.1111/j.1365-2125.1984.tb02410.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Symmetrical confidence intervals for bioequivalence trials.

Authors:  W J Westlake
Journal:  Biometrics       Date:  1976-12       Impact factor: 2.571

2.  Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.

Authors:  G M Frigo; E Perucca; M Teggia-Droghi; G Gatti; A Mussini; J Salerno
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

3.  Bioavailability--a problem in equivalence.

Authors:  C M Metzler
Journal:  Biometrics       Date:  1974-06       Impact factor: 2.571

4.  Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation.

Authors:  J P Boissel; E Wolf; J Gillet; A Soubrane; A Cavallaro; G Mazoyer; J P Delahaye
Journal:  Eur Heart J       Date:  1981-02       Impact factor: 29.983

5.  [Study of blood quinidine levels obtained by the administration of delayed-action quinidine].

Authors:  J Renais; L Scebat; J Lenègre
Journal:  Arch Mal Coeur Vaiss       Date:  1971-05

6.  Determination of quinidine and metabolites in urine by reverse-phase high-pressure liquid chromatography.

Authors:  M R Bonora; T W Guentert; R A Upton; S Riegelman
Journal:  Clin Chim Acta       Date:  1979-02-01       Impact factor: 3.786

7.  Determination of quinidine and its major metabolites by high-performance liquid chromatography.

Authors:  T W Guentert; P E Coates; R A Upton; D L Combs; S Riegelman
Journal:  J Chromatogr       Date:  1979-01-01

Review 8.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

  8 in total
  1 in total

1.  Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.

Authors:  Rongjun Zuo; Feng Li; Sweta Parikh; Li Cao; Kirsten L Cooper; Yulong Hong; Jin Liu; Ronald A Faris; Daochuan Li; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2017-01-06       Impact factor: 3.922

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.